P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY

Bibliographic Details
Published in:	HemaSphere
Main Authors:	P Rodríguez-Otero, J San-Miguel, LD Anderson, Jr, S Lonial, A Truppel-Hartmann, J Sanford, E Rowe, TB Campbell, N Munshi
Format:	Article
Language:	English
Published:	Wiley 2022-04-01
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000829656.69351.86

Internet